image: Quentin Vanhaelen, PhD, of Insilico Medicine will present PandaOmics, the company’s AI-powered target discovery platform, at the 9th Annual Conference on Research and Drug Discovery in Aging.
see After
Credit: c/o Insilico Medicine
The 9th Annual Aging Research and Drug Discovery Conference, from August 29 to September 29. 2 at the University of Copenhagen, will feature researcher Quentin Vanhaelen, PhD of Insilico Medicine, who will discuss the company’s artificial intelligence target discovery platform, PandaOmics. The platform has been validated by numerous drugs in development, including the first drug discovered and designed by AI for idiopathic pulmonary fibrosis, currently in phase I trials. Vanhaelen is one of more than 70 academic and industry leaders in longevity who will speak at the event and outline the progress PandaOmics has made since it was launched by Insilico in 2020.
PandaOmics uses aging as an important biomarker, sifting through billions of data points from clinical trials, research grants, and omics data samples, including transciptomics, genomics, epigenomics, and proteomics. The system identifies where aging and disease intersect and how aging contributes to poor health. Researchers used PandaOmics predict nine molecular targets for new drugs that can fight aging as well as diseases associated with aging, including Alzheimer’s disease, Parkinson’s disease, cirrhosis and rheumatoid arthritis.
Vanhaelen will discuss the possibilities of developing dual-use drugs using AI and explain how the PandaOmics platform works – using data to discover where age-related and non-aging-related diseases age overlap, and evaluating the therapeutic potential of targets by ranking them for toxicability and safety. And Vanhaelen will talk about the benefits of an AI approach, which allows scientists to make these discoveries in record time. The nine new dual-purpose targets for aging and disease were discovered and published in less than two months.
Identifying ways to identify and treat aging is one of many topics explored in relation to expanding human lifespan and health at ARDD. The conference, founded by Insilico Medicine Founder and CEO Alex Zhavoronkov, PhD, brings together longevity experts to share discoveries, collaborate and advance research on aging.
“This conference has been designed to create the world’s premier platform for the pharmaceutical industry to actively engage and integrate the latest findings from credible aging research into all aspects of their internal R&D strategy. “, said Zhavoronkov.
Vanhaelen has been working with Insilico since 2016 and holds a PhD in theoretical physics from the University of Brussels. He founded a consulting company called Insilicoscreen on signaling pathway dynamics analysis which was acquired by Insilico Medicine and his research interests include theories of aging, signaling pathway activation, systems modeling dynamics and applications of deep learning techniques for drug discovery.
He will present on PandaOmics on September 2, from 7:40 to 8 p.m. EST.
About the ARDD
The 9th Annual Conference on Aging Research and Drug Discovery (ARDD) brings together leading academic and industry speakers in the field of aging research with startups, venture capitalists and publishers of industry journals. The event will be held virtually and in person at the University of Copenhagen from August 29 to September 29. 2.
Details and registration: http://www.agingpharma.org/
About Insilico Medicine
Insilico Medicine, an end-to-end clinical-stage artificial intelligence (AI)-focused drug discovery company, connects clinical trial biology, chemistry and analytics using novel AI systems. generation. The company has developed AI platforms that use deep generative models, reinforcement learning, transformers and other modern machine learning techniques to discover new targets and design new molecular structures with desired properties. Insilico Medicine offers breakthrough solutions to discover and develop innovative drugs against cancer, fibrosis, immunity, central nervous system (CNS) diseases and age-related diseases.
For more information, visit www.insilico.com
For media inquiries, contact [email protected]
Research method
Press article
Research subject
Not applicable
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of press releases posted on EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.
